Evarrest

RSS

Withdrawn

This medicine's authorisation has been withdrawn

human fibrinogen / human thrombin
MedicineHumanWithdrawn

German is available via eTranslation, the European Commission's machine translation service.

Translate to German | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 15 November 2017, the European Commission withdrew the marketing authorisation for Evarrest (human fibrinogen / human thrombin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Omrix Biopharmaceuticals N. V., which notified the European Commission of its decision to permanently discontinue the marketing of the product in the EU for commercial reasons. 

Evarrest was granted marketing authorisation in the EU on 25 September 2013 for the treatment of haemostasis and as an adjunct to haemostasis in bleeding.

The European Public Assessment Report (EPAR) for Evarrest is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (597.14 KB - PDF)

Ansicht

español (ES) (515.07 KB - PDF)

Ansicht

čeština (CS) (578.52 KB - PDF)

Ansicht

dansk (DA) (518.89 KB - PDF)

Ansicht

Deutsch (DE) (516.28 KB - PDF)

Ansicht

eesti (ET) (518.26 KB - PDF)

Ansicht

ελληνικά (EL) (600.8 KB - PDF)

Ansicht

français (FR) (518 KB - PDF)

Ansicht

hrvatski (HR) (535.13 KB - PDF)

Ansicht

italiano (IT) (514.66 KB - PDF)

Ansicht

latviešu (LV) (593.61 KB - PDF)

Ansicht

lietuvių (LT) (538.4 KB - PDF)

Ansicht

magyar (HU) (571.9 KB - PDF)

Ansicht

Malti (MT) (577.35 KB - PDF)

Ansicht

Nederlands (NL) (514.67 KB - PDF)

Ansicht

polski (PL) (576.8 KB - PDF)

Ansicht

português (PT) (536.9 KB - PDF)

Ansicht

română (RO) (1020.06 KB - PDF)

Ansicht

slovenčina (SK) (100.5 KB - PDF)

Ansicht

slovenščina (SL) (567.85 KB - PDF)

Ansicht

suomi (FI) (513.9 KB - PDF)

Ansicht

svenska (SV) (514.56 KB - PDF)

Ansicht

Product information

български (BG) (1.55 MB - PDF)

Ansicht

español (ES) (896.44 KB - PDF)

Ansicht

čeština (CS) (1.51 MB - PDF)

Ansicht

dansk (DA) (813.54 KB - PDF)

Ansicht

Deutsch (DE) (845.01 KB - PDF)

Ansicht

eesti (ET) (787.41 KB - PDF)

Ansicht

ελληνικά (EL) (1.55 MB - PDF)

Ansicht

français (FR) (818.58 KB - PDF)

Ansicht

hrvatski (HR) (898.08 KB - PDF)

Ansicht

italiano (IT) (816.34 KB - PDF)

Ansicht

latviešu (LV) (1.31 MB - PDF)

Ansicht

lietuvių (LT) (910.1 KB - PDF)

Ansicht

magyar (HU) (1.15 MB - PDF)

Ansicht

Malti (MT) (1.31 MB - PDF)

Ansicht

Nederlands (NL) (827.81 KB - PDF)

Ansicht

polski (PL) (1.32 MB - PDF)

Ansicht

português (PT) (818.67 KB - PDF)

Ansicht

română (RO) (934.43 KB - PDF)

Ansicht

slovenčina (SK) (1.32 MB - PDF)

Ansicht

slovenščina (SL) (1.25 MB - PDF)

Ansicht

suomi (FI) (923.42 KB - PDF)

Ansicht

svenska (SV) (864.7 KB - PDF)

Ansicht

Íslenska (IS) (877.78 KB - PDF)

Ansicht

norsk (NO) (860 KB - PDF)

Ansicht
Latest procedure affecting product information:II/0027/G
15/11/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (496.48 KB - PDF)

Ansicht

español (ES) (460.12 KB - PDF)

Ansicht

čeština (CS) (486.03 KB - PDF)

Ansicht

dansk (DA) (460.06 KB - PDF)

Ansicht

Deutsch (DE) (459.93 KB - PDF)

Ansicht

eesti (ET) (459.94 KB - PDF)

Ansicht

ελληνικά (EL) (496.65 KB - PDF)

Ansicht

français (FR) (459.86 KB - PDF)

Ansicht

hrvatski (HR) (472.28 KB - PDF)

Ansicht

italiano (IT) (459.91 KB - PDF)

Ansicht

latviešu (LV) (489.48 KB - PDF)

Ansicht

lietuvių (LT) (474.86 KB - PDF)

Ansicht

magyar (HU) (484.42 KB - PDF)

Ansicht

Malti (MT) (490.05 KB - PDF)

Ansicht

Nederlands (NL) (459.69 KB - PDF)

Ansicht

polski (PL) (489.07 KB - PDF)

Ansicht

português (PT) (459.81 KB - PDF)

Ansicht

română (RO) (930.92 KB - PDF)

Ansicht

slovenčina (SK) (29.59 KB - PDF)

Ansicht

slovenščina (SL) (483.95 KB - PDF)

Ansicht

suomi (FI) (460.2 KB - PDF)

Ansicht

svenska (SV) (459.88 KB - PDF)

Ansicht

Íslenska (IS) (460 KB - PDF)

Ansicht

norsk (NO) (459.61 KB - PDF)

Ansicht

Product details

Name of medicine
Evarrest
Active substance
  • human fibrinogen
  • human thrombin
International non-proprietary name (INN) or common name
  • human fibrinogen
  • human thrombin
Therapeutic area (MeSH)
Hemostasis
Anatomical therapeutic chemical (ATC) code
B02BC30

Pharmacotherapeutic group

Local hemostatics

Therapeutic indication

Supportive treatment in adult surgery where standard surgical techniques are insufficient (see section 5.1):

- for improvement of haemostasis.

Authorisation details

EMA product number
EMEA/H/C/002515
Marketing authorisation holder
Omrix Biopharmaceuticals N. V.

Leonardo Da Vinci Laan 15
1831 Diegem
Belgium

Marketing authorisation issued
25/09/2013
Withdrawal of marketing authorisation
15/11/2017
Revision
4

Assessment history

This page was last updated on

Share this page